Blueprint Medicines
Cambridge
About Blueprint Medicines
Blueprint Medicines develops targeted therapies for cancer and blood disorders, focusing on precision medicine. The company utilizes genetic insights to design treatments tailored to individual patient needs. Their portfolio includes products aimed at specific mutations and conditions, enhancing treatment options for patients with various types of cancer and hematologic diseases. Blueprint Medicines collaborates with healthcare providers to ensure that their therapies are accessible and effectively integrated into patient care. Through ongoing research and development, the company aims to expand its offerings and address unmet medical needs in oncology and hematology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $500K – $1M
- Total funding: $2.4B
- Funding stage: M&A
- Last round: Post-IPO Equity (Jun 2022)
- Ticker: nasdaq:BPMC
- Website: blueprintmedicines.com
- Phone: +1 617 374 7580
Industries & Categories
Bioinformatics, Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/blueprint-medicines-30596 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.